Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
about
Oral naltrexone maintenance treatment for opioid dependenceOral naltrexone maintenance treatment for opioid dependenceIntermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependenceA Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid AddictionEndogenous opiates and behavior: 2006Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence.Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceManagement of relapse in naltrexone maintenance for heroin dependence.Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewOpioid detoxification and naltrexone induction strategies: recommendations for clinical practice.Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomesUse of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not availableEarly outcomes following low dose naltrexone enhancement of opioid detoxification.Pharmacologic treatments for opioid dependence: detoxification and maintenance options.Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexoneTreating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial.Baseline characteristics of patients predicting suitability for rapid naltrexone induction.Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.Long-acting injectable naltrexone for the management of patients with opioid dependence.The use of incentives to reinforce medication adherence.Financial reinforcers for improving medication adherence: findings from a meta-analysis.A perfect platform: combining contingency management with medications for drug abuseLinkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification.Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.Treatment of co-occurring alcohol and other drug use disorders.Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.Excess mortality among opioid-using patients treated with oral naltrexone in Australia.Antagonist Models for Relapse Prevention and Reducing HIV Risk.Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders.Effects of Tai Chi on the protracted abstinence syndrome: a time trial analysis.Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.Advances in the delivery of buprenorphine for opioid dependence.
P2860
Q24235092-CC2799EC-928B-4EF8-8174-5B7CF4E80D07Q24236708-40ABD3C4-9D9F-4753-ADA1-330B1E7C59BCQ24645054-76217BD8-34C2-479B-BF31-4BE264D45D7CQ28069995-709B569C-6243-4C1B-AAB9-1ED1321CE4B7Q28752585-30B8E78D-2562-400A-9657-81F9CE4E0CBAQ30252443-700A87C1-6753-40F6-B294-A78F0B289BFBQ33704889-DB7EF27D-0D58-4A9E-B881-CCA41FED8380Q33783250-9E1026D5-CE18-4775-BF1D-79DFB338AA06Q34128519-3923704F-0440-430E-9C25-D387D41A523AQ34280076-05C65C9C-DC25-49AB-8EF4-A5A6A4712171Q35084340-DFE6C513-A06F-4BB8-B654-3D31BF7DF208Q35090939-DD7EC676-CFBF-4C98-BEB6-E695C5F184A7Q35118798-FB2FCC56-D2D8-4CB0-9DC2-2D4794E3A99EQ35178521-E3A0B57B-1B44-48FE-8AB5-2D5F332C1CA7Q35303819-1380B243-15EA-4135-942B-73C999D70887Q35454866-59405CBB-2007-4FCC-947C-8EF2A8D91A0CQ35619851-54D8B813-B8B7-4405-A372-97A95E379738Q35670689-5413D448-C743-4A4B-8309-CF0548E324BDQ35673205-E1F62EED-FF16-4EDC-B7DD-30C0C15D5717Q35834292-4DF9EFC1-72A4-4B03-AFCB-C163CA1AA006Q35911283-E482A429-EED8-4425-90E7-5D36CBC083EEQ35952033-DA8A773C-2A9D-453F-AFFE-8B0493E6CD62Q36139018-3D63D71A-707C-47B2-81BD-6D1307E87D78Q36179591-91987999-A428-4001-8FBC-B0C97E35ECBAQ36204996-283C49F6-9DAE-44E6-91FA-495F8B6B29C6Q36631554-65340926-57D5-46F2-ABB5-573AEC1C9432Q36757815-F22D5929-A0B6-49C5-9C9F-61D4F885B46BQ36808909-BDEF6E02-9F04-460F-91B7-A65649C5BC73Q37386522-A82AA996-026D-4A3D-AC60-7804A8667FC8Q37700707-F96E341C-BF99-474C-B9AF-ED79571F0CABQ38258810-D47C9735-C74F-4C7B-B386-2B1F99E9BD40Q38382530-0A5018F4-D979-4A5B-B2C3-9022625BB110Q38389915-FAD342EB-B964-4D23-B63B-C74EE20C2A36Q38843745-E8DCCBDB-F7B0-49CC-AD93-8C7DDE342F77Q39481754-73C8B833-8711-43CD-A38E-E22C4F6808F5Q40112906-266BBCE8-E364-4E45-A57C-DF73C29CDA6EQ42289728-038AD73E-13A5-4318-9F4D-BDB23CC8D3FFQ44333905-848F152F-8244-4AEA-AF25-28099B268BE1Q44342511-31D3FA26-CF11-4965-BA79-49320F8F1031Q45946172-EA4D7C0B-879F-440F-8DC2-34C52C4DDBAD
P2860
Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@ast
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@en
type
label
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@ast
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@en
prefLabel
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@ast
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@en
P2093
P2860
P1476
Behavioral therapy to augment ...... e: a ceiling on effectiveness?
@en
P2093
Edward V Nunes
Herbert D Kleber
Jami L Rothenberg
Kenneth M Carpenter
Maria A Sullivan
P2860
P304
P356
10.1080/00952990600918973
P577
2006-01-01T00:00:00Z